isoxazoles has been researched along with Compensatory Hyperinsulinemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baldelli, F; Cipriani, S; D'Amore, C; Distrutti, E; Fiorucci, S; Mencarelli, A; Palladino, G; Renga, B | 1 |
| Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Wong, D | 1 |
| Matsui, K; Nagao, K; Shibata, T; Shinkai, H; Wakitani, K; Yonemori, F | 1 |
| Fujita, T; Haneda, M; Hidaka, H; Kashiwagi, A; Kikkawa, R; Kojima, H; Maegawa, H; Morino, K; Nishio, Y; Obata, T; Shibata, T; Ugi, S; Yasuda, H | 1 |
4 other study(ies) available for isoxazoles and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Bile Acids and Salts; Blood Glucose; Cardiovascular Diseases; Chenodeoxycholic Acid; Dyslipidemias; Fibrosis; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Isoxazoles; Lipid Metabolism; Liver; Myocardium; Obesity; PPAR alpha; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Risk Factors; RNA, Messenger; Triglycerides | 2013 |
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Dibenzocycloheptenes; Fasting; Female; Glucose Clamp Technique; Glucose Tolerance Test; Heterocyclic Compounds, 4 or More Rings; Hyperinsulinism; Insulin Resistance; Isoxazoles; Metabolism; Olanzapine; Piperidines; Rats; Rats, Sprague-Dawley | 2013 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Isoxazoles; Male; Mice; Mice, Inbred Strains; Oxidation-Reduction; Pioglitazone; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1999 |
A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle.
Topics: Animals; Blood Glucose; Drug Synergism; Glucose; Glucose Clamp Technique; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Immunosorbent Techniques; Insulin; Isoxazoles; Male; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphotyrosine; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Insulin; Signal Transduction | 1999 |